BCOP key terms

The delivered dose of a chemotherapy regimen as a percentage of the planned standard dose over time, accounting for both dose reductions and treatment delays; low values can worsen survival in curable cancers.

An equation used to calculate a carboplatin dose from a target area under the curve and the patient's glomerular filtration rate, avoiding the need for measured drug exposure.

Measuring blood concentrations of a drug at set times to individualize dosing, used for agents with narrow therapeutic indices such as busulfan, methotrexate, and tacrolimus.

Checking germline DNA for variants such as DPYD or TPMT and NUDT15 before giving fluoropyrimidines or thiopurines, so doses can be reduced or drugs avoided to prevent severe toxicity.

A change in antineoplastic metabolism caused by a coadministered drug that inhibits or induces enzymes such as CYP3A4, raising toxicity risk or lowering efficacy; common with azole antifungals and anticonvulsants.

An inactive compound that must be converted in the body, usually by liver enzymes, into its active form; examples include cyclophosphamide, capecitabine, and irinotecan, which becomes SN-38.

The lowest blood cell counts reached after myelosuppressive chemotherapy, usually seven to fourteen days after treatment, used to plan blood count checks and later dose adjustments.

An estimate of kidney function derived from age, weight, sex, and serum creatinine, used to adjust doses of renally cleared drugs and to judge eligibility for nephrotoxic agents.

Calculating an antineoplastic dose from a patient's height and weight, a standard approach for cytotoxic agents despite wide variation in drug exposure between individual patients.

A biologic product shown to be highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency; it is licensed through an abbreviated pathway.

Fever of 38.3 degrees Celsius or higher once, or 38.0 degrees sustained for an hour, with an absolute neutrophil count under 500 cells per microliter; a medical emergency needing empiric antibiotics.

A metabolic emergency caused by rapid cancer cell breakdown, producing high potassium, uric acid, and phosphate with low calcium, which can cause kidney injury, seizures, and arrhythmias.

Leakage of a vesicant or irritant antineoplastic drug from the vein into surrounding tissue during infusion, causing pain, blistering, and tissue necrosis that may require surgical debridement.

A systemic inflammatory response after CAR T-cell or bispecific antibody therapy marked by fever, hypotension, and hypoxia; graded by severity and treated with supportive care, tocilizumab, and corticosteroids.

Immune effector cell-associated neurotoxicity syndrome: neurologic toxicity after immune effector cell therapy showing as confusion, expressive aphasia, tremor, seizures, or cerebral edema; scored with a standardized tool and treated with corticosteroids.

Inflammation of normal organs caused by immune checkpoint inhibitors, commonly affecting skin, colon, lung, liver, thyroid, and pituitary; graded by severity and managed with treatment holds and corticosteroids.

Painful redness and ulceration of the mouth lining caused by chemotherapy or head and neck radiation, peaking about one to two weeks after treatment and worsening nutrition and infection risk.

Cumulative sensory nerve damage from taxanes, platinum compounds, or vinca alkaloids producing numbness, tingling, and pain in the hands and feet; may require dose reduction, delay, or discontinuation.

Dose-related heart muscle injury from doxorubicin, daunorubicin, or related agents that can reduce left ventricular ejection fraction and cause heart failure, monitored with imaging and limited by cumulative dose caps.

Fever, chills, rigors, rash, or breathing difficulty occurring during or soon after infusion of a monoclonal antibody or other biologic, managed by pausing or slowing the infusion and giving premedications.

Donor immune cells attacking recipient tissues after allogeneic hematopoietic cell transplant, producing skin rash, jaundice, and diarrhea; acute and chronic forms are prevented and treated with immunosuppressive drugs.

A standardized severity score from one (mild) to five (death) for adverse events, used in trials and practice to describe toxicity and to guide dose modification.

Interdisciplinary care that relieves symptoms and improves quality of life for patients with serious illness and their caregivers, delivered alongside disease-directed treatment rather than only at the end of life.

A standardized rating of how well a patient carries out daily activities, such as the ECOG or Karnofsky scale, used to choose treatment, judge trial eligibility, and estimate prognosis.

Switching a patient from one opioid to another using equianalgesic tables to improve pain control or reduce side effects, with an added dose reduction to account for incomplete cross-tolerance.

The dose of one opioid that produces roughly the same pain relief as a dose of another opioid, used as a starting point when converting between agents and routes.

Blockage of the intestine by tumor, adhesions, or altered motility in advanced cancer; often managed with nasogastric decompression, antisecretory drugs, and opioids rather than routine surgery.

A persistent, distressing tiredness out of proportion to recent activity that does not improve with rest; screened routinely and managed with exercise, sleep support, and correction of contributing causes.

A written summary given at the end of treatment listing the therapies received, possible late effects, recommended surveillance tests, and lifestyle advice, shared with the patient and primary care clinician.

Giving guideline-based antiemetics before chemotherapy, selected by the regimen's emetogenic risk and patient factors, to prevent acute and delayed nausea and vomiting.

Routine colony-stimulating factor started in the first cycle when a regimen carries roughly a 20 percent or higher risk of febrile neutropenia, preventing infection and preserving dose intensity.

The first study in humans, designed mainly to define safety, dose-limiting toxicities, and the dose recommended for later testing, often with intensive pharmacokinetic and biomarker sampling.

A prespecified serious toxicity, defined by type, grade, and time window, that determines whether a dose level can be escalated in a phase I study.

The highest dose level at which no more than a set fraction of treated patients experience a dose-limiting toxicity, commonly used to pick a starting dose for phase II testing.

A standardized rule set for measuring tumor size on imaging and classifying response as complete, partial, stable, or progressive disease, allowing consistent comparison across solid tumor trials.

An analysis that includes every randomized participant in the group they were assigned to, regardless of adherence or crossover, preserving the protection against bias that randomization provides.

A study designed to show that a new treatment is not unacceptably worse than the standard by more than a prespecified margin, common for biosimilars and de-escalation strategies.

A regulatory pathway that lets patients with serious or life-threatening illness receive an investigational drug outside a clinical trial when no satisfactory alternative therapy exists.

An international ethical and scientific quality standard governing the design, conduct, recording, and reporting of trials that involve human participants, protecting subjects and ensuring credible data.